Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Ascendis Pharma ( (ASND) ).
On March 17, 2026, Ascendis Pharma reported positive Week 52 topline data from its New InsiGHTS Phase 2 trial in the U.S. evaluating once-weekly TransCon hGH versus daily somatropin in prepubertal children aged 1 to 10 with Turner syndrome. Children on TransCon hGH achieved an annualized height velocity of 9.05 cm per year, essentially identical to 9.04 cm per year with daily somatropin, despite receiving a lower mean weekly dose.
The study also showed TransCon hGH had a safety and tolerability profile comparable to daily somatropin, with adverse events largely mild to moderate and no treatment discontinuations through up to 143 weeks of follow-up. These results support TransCon hGH as a potentially competitive once-weekly alternative to daily injections in Turner syndrome, potentially strengthening Ascendis Pharma’s position in the growth hormone therapy market.
The most recent analyst rating on (ASND) stock is a Buy with a $273.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
The score is driven primarily by improving fundamentals (rapid revenue growth, strong margins, and a move to positive operating/free cash flow) but is held back by balance-sheet risk (negative equity and high debt) and unprofitable earnings (negative P/E). Technicals are neutral-to-slightly cautious, while the latest earnings call adds support via upbeat guidance and commercial/pipeline momentum despite elevated operating expenses and near-term volatility risks.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on developing and commercializing long-acting therapies for rare endocrine diseases. Its lead product, TransCon hGH (lonapegsomatropin), is approved in the U.S. and other markets for pediatric growth hormone deficiency, with an expanding focus on broader growth-related disorders.
Average Trading Volume: 709,181
Technical Sentiment Signal: Buy
Current Market Cap: $14.18B
See more insights into ASND stock on TipRanks’ Stock Analysis page.